Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

OBJECTIVE: For systematic reviews, no guidance exists for what review methods support valid conclusions of equivalence (EQ) and noninferiority (NI). To provide such guidance, we convened a workgroup of 13 experienced systematic reviewers from seven evidence-based practice centers (EPCs) and the Agency for Healthcare Research and Quality (AHRQ). STUDY DESIGN AND SETTING: The Lead EPC first performed two methods projects intended to assist the workgroup in clarifying the context, prioritizing the issues, targeting the scope, and summarizing the state of the art. RESULTS: Based on expert opinion, we devised guidance in four areas: 1) Unique risk of bias issues for trials self-identifying as EQ-NI trials; 2) Setting the reviewer's minimum important difference; 3) Analytic foundations for concluding EQ or NI; and 4) Language considerations when concluding EQ or NI. CONCLUSION: This article summarizes the main recommendations, and the full guidance chapter appears on the AHRQ Web site.

More information Original publication

DOI

10.1016/j.jclinepi.2012.05.001

Type

Journal article

Publication Date

2012-11-01T00:00:00+00:00

Volume

65

Pages

1144 - 1149

Total pages

5

Keywords

Bias, Clinical Trials as Topic, Comparative Effectiveness Research, Evidence-Based Medicine, Guidelines as Topic, Humans, Review Literature as Topic, Terminology as Topic, Therapeutic Equivalency, United States, United States Agency for Healthcare Research and Quality